New York State Common Retirement Fund Has $3.47 Million Stake in Roivant Sciences Ltd. $ROIV

New York State Common Retirement Fund grew its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 25.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 229,037 shares of the company’s stock after purchasing an additional 46,344 shares during the quarter. New York State Common Retirement Fund’s holdings in Roivant Sciences were worth $3,465,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. CWM LLC lifted its position in shares of Roivant Sciences by 44.6% during the 2nd quarter. CWM LLC now owns 2,984 shares of the company’s stock worth $34,000 after purchasing an additional 920 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its holdings in shares of Roivant Sciences by 1.2% during the third quarter. Oregon Public Employees Retirement Fund now owns 86,652 shares of the company’s stock worth $1,311,000 after buying an additional 1,019 shares during the last quarter. M&T Bank Corp boosted its position in shares of Roivant Sciences by 10.2% in the second quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock valued at $144,000 after acquiring an additional 1,181 shares during the period. Federated Hermes Inc. boosted its position in shares of Roivant Sciences by 4.8% in the third quarter. Federated Hermes Inc. now owns 29,069 shares of the company’s stock valued at $440,000 after acquiring an additional 1,320 shares during the period. Finally, GAMMA Investing LLC grew its stake in shares of Roivant Sciences by 16.6% in the third quarter. GAMMA Investing LLC now owns 9,302 shares of the company’s stock worth $141,000 after acquiring an additional 1,324 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors.

Trending Headlines about Roivant Sciences

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Positive Phase 2 BEACON results for brepocitinib in cutaneous sarcoidosis — the first industry‑sponsored, placebo‑controlled positive readout in this indication, which strengthens Roivant’s dermatology franchise and is the primary catalyst behind the stock move today. Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis
• Positive Sentiment: Pipeline progress: Pulmovant (a Roivant company) completed enrollment in the Phase 2 PHocus study of mosliciguat for PH‑ILD, reducing near‑term execution risk on that program and supporting long‑term value of Roivant’s portfolio. Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study
• Neutral Sentiment: Roivant filed Q3 results and held an earnings call — investors should review the call transcript and slide deck for management commentary on milestones, cash runway, and timelines for upcoming readouts that could drive future moves. Roivant Sciences Ltd. (ROIV) Q3 2025 Earnings Call Transcript
• Negative Sentiment: Mixed/weak near‑term financials: the quarter showed a loss and revenue below some analyst expectations (company reported low single‑digit millions in revenue), which creates short‑term earnings pressure despite the clinical wins; watch guidance and cash burn commentary. Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates

Analysts Set New Price Targets

ROIV has been the subject of several research analyst reports. Citigroup upped their target price on shares of Roivant Sciences from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th. Weiss Ratings restated a “hold (c-)” rating on shares of Roivant Sciences in a report on Thursday, January 22nd. The Goldman Sachs Group increased their target price on shares of Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Guggenheim reissued a “buy” rating and set a $28.00 target price on shares of Roivant Sciences in a research report on Thursday, December 18th. Finally, Leerink Partners boosted their price target on Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $25.19.

Roivant Sciences Price Performance

Shares of ROIV stock opened at $25.86 on Friday. The stock’s fifty day simple moving average is $22.07 and its 200 day simple moving average is $17.81. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $25.95. The firm has a market cap of $17.99 billion, a price-to-earnings ratio of -22.10 and a beta of 1.22.

Insiders Place Their Bets

In related news, CFO Richard Pulik sold 406,731 shares of the stock in a transaction dated Tuesday, December 23rd. The shares were sold at an average price of $22.43, for a total transaction of $9,122,976.33. Following the completion of the sale, the chief financial officer owned 239,413 shares in the company, valued at $5,370,033.59. This trade represents a 62.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Mayukh Sukhatme sold 1,018,995 shares of the business’s stock in a transaction dated Wednesday, December 31st. The shares were sold at an average price of $21.71, for a total transaction of $22,122,381.45. Following the completion of the transaction, the insider owned 20,267,429 shares in the company, valued at approximately $440,005,883.59. This trade represents a 4.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 12,132,392 shares of company stock worth $262,349,645 in the last quarter. 10.80% of the stock is owned by corporate insiders.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.